Understand the source comparison
Glutathione Peptide: Research Applications Comparison
Oxidative stress mitigation Direct ROS scavenging + regeneration via glutathione reductase 50–500 mg/kg in rodent models; human equivalent 250–2000mg oral or IV 30–60% reduction in lipid peroxidation markers (MDA, 4-HNE); increased GSH:GSSG ratio Effective whe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Oxidative stress mitigation
- Direct ROS scavenging + regeneration via glutathione reductase
- 50–500 mg/kg in rodent models; human equivalent 250–2000mg oral or IV
- 30–60% reduction in lipid peroxidation markers (MDA, 4-HNE); increased GSH:GSSG ratio
- Effective when delivered IV or intraperitoneally; oral delivery shows inconsistent results due to degradation
- Liver detoxification support
- Glutathione conjugation via GST enzymes; phase II clearance of xenobiotics
- 600–1200mg oral daily in clinical trials; liposomal or acetylcysteine precursor preferred
- Acetaminophen toxicity studies show 70% reduction in hepatocellular injury when GSH pre-loaded
- Precursor loading (NAC) more reliable than direct glutathione for hepatoprotection
- Immune function modulation
- T-cell proliferation requires intracellular GSH; NK cell cytotoxicity correlates with GSH levels
- 500–1000mg oral daily in immunocompromised populations
- T-cell counts increased 12–18% in HIV patients; cytokine production normalized
- Efficacy depends on baseline GSH depletion. Minimal effect in healthy subjects
- Neuroprotection studies
- Maintains mitochondrial GSH pool; prevents protein aggregation via thiol protection
- Intranasal or IV delivery 100–500mg in animal models
- 40–50% reduction in dopaminergic neuron loss in MPTP Parkinson's models
- Blood-brain barrier limits systemic delivery; intranasal or liposomal formulations required